Advanced Cell Technology, Inc. (OTC: ACTC) Enrolls First 2 Patients in Phase 1/2 Clinical Trials

On June 16, 2011, Advanced Cell Technology, Inc. (OTC: ACTC) announced the enrollment of the first patients in its two Phase 1/2 clinical trials for Stargardt’s Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD).

Without releasing the patients’ names, the Company said that the patients were enrolled at the Jules Stein Eye Institute at the University of California, Los Angeles. Both trials will test the safety and tolerability of retinal pigment epithelial, or RPE cells, which ACT makes from human embryonic stem cells. Each study will enroll 12 patients, with groups of three testing different doses of the cells.

Principal investigator Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at the Jules Stein Eye Institute at UCLA, said, “These trials mark a significant step toward addressing what is one of the largest unmet medical needs of our time — treatments for otherwise untreatable and common forms of legal blindness, Dry AMD, SMD and other forms of atrophic macular degeneration.  Dry AMD is the most common form of macular degeneration.  It is the leading cause of blindness in the developed world, and is the leading cause of blindness in people over the age of 55. The incidence of Dry AMD is expected to double over the next 20 years as the population ages.”

Shares of the company went up by 0.16% to $0.189 with volume of 2.84 million shares traded. The 52 week range of the stock is $0.04-$0.27. The market cap of the stock stands at $291.65 million with beta of -2.22.

Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine.


The assembled information distributed by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented herein. will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial advisor.

Our Research Report on is now available. Don´t Trade until you Read our FREE FULL REPORT. Click Here